You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

AMD, nAMD, wet AMD, RTH258, brolucizumab, switch

Showing 1 - 25 of 2,182
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Age-related Macular Degeneration, Macular Degeneration, Wet Macular Degeneration Trial in Germany, Switzerland (Brolucizumab)

Recruiting
  • Age-related Macular Degeneration
  • +5 more
  • Brolucizumab
  • Regensburg, Bavaria, Germany
  • +32 more
Jan 20, 2023

Age-related Macular Degeneration (AMD) Trial (brolucizumab)

Withdrawn
  • Age-related Macular Degeneration (AMD)
  • (no location specified)
Sep 21, 2021

Age-Related Macular Degeneration, Macular Degeneration, Wet Macular Degeneration Trial in Phoenix, Abilene, Arecibo

Completed
Has Results
  • Age-Related Macular Degeneration
  • +5 more
  • brolucuzumab 6 mg IVT
  • Phoenix, Arizona
  • +2 more
Dec 9, 2020

Neovascular Age Related Macular Degeneration Trial in France (RTH258/Brolucizumab)

Active, not recruiting
  • Neovascular Age Related Macular Degeneration
  • Nice, Cedex1, France
  • +39 more
Jan 20, 2023

Age-Related Macular Degeneration Trial in Hong Kong (Brolucizumab, Aflibercept)

Recruiting
  • Age-Related Macular Degeneration
  • Hong Kong, Hong Kong
    Grantham Hospital
Jan 25, 2023

Ocular Adverse Events in Neovascular Age-related Macular

Completed
  • Age-related Macular Degeneration (AMD)
  • Aflibercept
  • +2 more
  • East Hanover, New Jersey
    Novartis Investigative Site
Dec 15, 2021

Neovascular Age-related Macular Degeneration

Completed
  • Age-related Macular Degeneration (AMD)
  • East Hanover, New Jersey
    Novartis Investigative Site
Dec 15, 2021

Neovascular Age-related Macular Degeneration Enrolled in

Completed
  • Age-related Macular Degeneration (AMD)
  • All participants
  • East Hanover, New Jersey
    Novartis Investigative Site
Oct 6, 2021

Ocular Adverse Events in Neovascular Agerelated Macular

Completed
  • Age-related Macular Degeneration (AMD)
  • Aflibercept
  • +2 more
  • East Hanover, New Jersey
    Novartis Investigative Site
Dec 15, 2021

Neovascular Age-related Macular Degeneration

Completed
  • Age-related Macular Degeneration (AMD)
  • East Hanover, New Jersey
    Novartis Pharmaceuticals
Oct 19, 2021

Fluid Resolution and Effectiveness of Brolucizumab for nAMD in

Recruiting
  • Neovascular Age-related Macular Degeneration (nAMD)
  • Funchal, Portugal
  • +11 more
Jun 9, 2022

Patients With nAMD in UK Routine Clinical Practice

Recruiting
  • Neovascular Age-related Macular Degeneration
  • brolucizumab
  • Peterborough, Cambridgeshire, United Kingdom
  • +12 more
Jul 18, 2022

Neovascular Age-related Macular Degeneration Trial in Italy (Brolucizumab)

Recruiting
  • Neovascular Age-related Macular Degeneration
  • Ancona, AN, Italy
  • +18 more
Aug 10, 2022

Neovascular Age-related Macular Degeneration Trial in Worldwide (brolucizumab)

Active, not recruiting
  • Neovascular Age-related Macular Degeneration
  • Huntington Beach, California
  • +59 more
Jan 20, 2023

Patients Receiving Beovu in Neovascular Age-related Macular

Recruiting
  • Neovascular Age-related Macular Degeneration (nAMD)
  • Luedenscheid, NRW, Germany
  • +48 more
Sep 16, 2022

Neovascular Age-related Macular Degeneration Trial in Binningen (Brolucizumab 6 mg solution for intravitreal injection)

Terminated
  • Neovascular Age-related Macular Degeneration
  • Brolucizumab 6 mg solution for intravitreal injection
  • Binningen, Baselland, Switzerland
    Vista Klinik
Dec 8, 2021

Neovascular Age-related Macular Degeneration Trial (FT-003)

Not yet recruiting
  • Neovascular Age-related Macular Degeneration
  • FT-003
  • (no location specified)
Nov 21, 2022

Neovascular Age-related Macular Degeneration Trial in Graz (Aflibercept 40 MG/ML, Faricimab 120 MG/ML)

Recruiting
  • Neovascular Age-related Macular Degeneration
  • Aflibercept 40 MG/ML
  • Faricimab 120 MG/ML
  • Graz, Styria, Austria
    Department of Ophthalmolgy, Medical University Graz
Jul 3, 2023

AMD, nAMD, Wet Age-related Macular Degeneration Trial in United States (RGX-314 Dose 1, RGX-314 Dose 2, Aflibercept (EYLEA®))

Recruiting
  • AMD
  • +5 more
  • RGX-314 Dose 1
  • +2 more
  • Encino, California
  • +16 more
Jun 2, 2022

Neovascular Age-related Macular Degeneration Trial in Puerto Rico, United States (Brolucizumab 6 mg, Aflibercept 2 mg)

Completed
Has Results
  • Neovascular Age-related Macular Degeneration
  • Brolucizumab 6 mg
  • Aflibercept 2 mg
  • Peoria, Arizona
  • +64 more
Dec 9, 2020

Neovascular Age-related Macular Degeneration(nAMD) Trial in Shanghai, Tianjin (HG202)

Not yet recruiting
  • Neovascular Age-related Macular Degeneration(nAMD)
  • HG202
  • Shanghai, Shanghai, China
  • +1 more
Sep 4, 2023

Russian Registry of Patients With nAMD

Terminated
  • Neovascular Age-Related Macular Degeneration
  • nAMD
  • (no location specified)
Jan 16, 2023

Neovascular Age-Related Macular Degeneration (nAMD) Trial in United States (RGX-314 Dose 1, RGX-314 Dose 2, Ranibizumab

Recruiting
  • Neovascular Age-Related Macular Degeneration (nAMD)
  • RGX-314 Dose 1
  • +3 more
  • Phoenix, Arizona
  • +14 more
Mar 29, 2022

Neovascular Age-Related Macular Degeneration Trial in China (Brolucizumab 6mg, Aflibercept 2 mg)

Recruiting
  • Neovascular Age-Related Macular Degeneration
  • Brolucizumab 6mg
  • Aflibercept 2 mg
  • Guangzhou, Guangdong, China
  • +30 more
Jan 20, 2023

OCT Angiography in Wet AMD

Recruiting
  • Neovascular (Wet) Age-related Macular Degeneration (AMD)
  • Optical Coherence Tomography
  • Portland, Oregon
    Casey Eye Institute, Oregon Health & Science University
Sep 20, 2022